新诊断胶质母细胞瘤初次与二次切除标本中PD-1阳性细胞的评估及其对患者结局的意义
本研究纳入16例新诊断WHO IV级胶质母细胞瘤患者,比较初次与二次切除肿瘤标本中PD-1、PD-L1等免疫标志物表达变化及其与临床结局的关系。结果发现二次切除标本中肿瘤浸润淋巴细胞CD3、CD8、PD-1显著增高(p≤0.05),二次标本PD-1高表达组与较长无进展生存和复发后较短生存相关。
要点
- 二次切除标本中肿瘤浸润淋巴细胞CD3、CD8、PD-1较初次标本显著增高(p≤0.05)。
- 初次及二次切除标本肿瘤细胞均表达PD-L1。
- 二次标本PD-1高表达与较长无进展生存和复发后较短生存相关。
核心结论
- 二次切除标本PD-1高表达患者二次手术后预后较差。
- PD-1/PD-L1通路可能与胶质母细胞瘤二次手术后的患者结局相关。
研究设计与样本
- 研究纳入16例年龄14至65岁、组织学证实WHO IV级胶质母细胞瘤患者,原发肿瘤切除时间为2008年至2014年,接受分次放疗和替莫唑胺治疗。
- 其中4例接受自体福尔马林固定肿瘤疫苗免疫治疗。
- 所有患者均在肿瘤复发后24个月内接受二次切除。
- 对初次和二次切除肿瘤标本进行免疫系统分子标志物免疫组化检测,评估标志物表达与临床结局的相关性。
主要发现
- 二次切除标本中肿瘤浸润淋巴细胞CD3、CD8和PD-1较初次切除标本显著增高(p≤0.05)。
- 所有患者初次和二次切除标本肿瘤细胞均表达PD-L1。
- 按初次或二次切除标本PD-1免疫组化评分中位数分为高表达组和低表达组,初次切除标本PD-1或PD-L1高、低表达组间患者结局无显著差异。
- 二次切除标本高表达组中多数患者评分较初次切除肿瘤标本增高。
- 二次切除标本PD-1高表达评分组与较长无进展生存和复发后较短生存相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glioblastoma (GBM) is the most common type of malignant brain tumor and has a very poor prognosis. Most patients relapse within 12 months despite aggressive treatment and patient outcome after recurrent is extremely worse. This study was designed to clarify the change of the molecular expression, including programmed cell death 1 (PD-1) and PD-ligand 1 (PD-L1), on the initial and secondary resected tumor specimens and to address the influence of these expressions for patient outcome after second surgery of glioblastoma. We investigated 16 patients, ranging in age from 14 to 65 years, with histologically verified WHO grade IV GBM, whose original tumor was resected between 2008 and 2014, and treated with fractionated radiotherapy and temozolomide. Four patients who were treated with immunotherapy using autologous formalin-fixed tumor vaccine were enrolled. All of the patients underwent secondary resection after tumor recurrence within 24 months. We carried out an immunohistochemical examination of the initial and secondary resected tumors from patients using a panel of immune system molecular markers, and assessed whether marker expression correlated with clinical outcomes. CD3, CD8 and PD-1 on tumor-infiltrating lymphocytes was significantly increased in secondary resected specimens compared with initially resected specimens (p ≤ 0.05). All patients expressed PD-L1 on tumor cells in initial and secondary resection specimens. Patients were divided into high or low expression group by median IHC score of PD-1 on initial or secondary resected specimens. No significant differences in patient outcomes were observed between high and low PD-1 or PD-L1 groups of initially resected specimens. In high expression group of secondary resected specimens, most patients score had increased which compared with initial resected tumor specimens. The PD-1 high expression score group of secondary resected specimens was associated with long progression-free survival and short survival after recurrence. PD-L1 expression was detected in almost all initial and secondary specimens. Patients with high PD-1 expression of secondary specimen had bad prognosis after secondary resection. PD-1/PD-L1 pathway may be associated with patient outcome after second surgery of glioblastoma.
引用
- Miyazaki T, Ishikawa E, Matsuda M, et al. Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome. J Neurooncol. 2017. PMID: 28447277. doi:10.1007/s11060-017-2451-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。